BioWorld MedTech

June 27, 2016

Resistant superbug s arrival highlights the need for more effective diagnostic products

Politicians and medical experts worldwide alike have decried the lack of innovation in antibiotics an area that has been neglected for three decades but another area is turning out to be just as important: diagnostics. Read More

Cut the blame game, infection control is a shared problem

What s inside your IV catheter?

Med-tech industry tries to find footing in wake of affirmative Brexit vote

FDA informs Franken MDRs offer no news on Medtronic s Infuse

South Korea cautiously considering 3-D printed medical instruments

Other news to note

Product briefs

MDD's Company Stock Report

Appointments and advancements

Neurology Extra

Rapid point-of-care tests for anti-microbial resistance

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

Roche reports new TREM2 agonists

BioWorld Science

F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...

Genescience presents STAT6 degrader for atopic dermatitis

BioWorld Science

Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....

Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis

BioWorld Science

Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...